This same stock popped for big time gains last week! Want profits of 100% or more? Read now.
This stock is ready to fly yet again!
Are you looking for a stock that could double in a single day? Then this stock is exactly what you're looking for.
In fact, just a week ago I alerted this same stock and the thing gained over 66% in a single day... and that's strictly speaking about the gain over the open price!
Every stock that I've alerted that gained over 100% in a single day had a small float. Remember, a float represents the number of shares available to the public. The less shares available and the higher the demand the more likely share prices are to skyrocket.
It's kind of like looking for the latest craze around Christmas time. Everyone buys the item up and then you can't find them in stores, but they're on sale on Ebay for 10x the original price. The same idea applies here.
This stock's float is worth about $130k meaning that shares could easily double if the float is traded in one day. The best part? This happens quite often in the small cap arena and has happened with my alerts a lot.
Last week the stock was trading at 7 cents a share before gaining 66% in one trading session.
Now imagine what could happen now that the stock pulled back and is now trading at just 5 cents a share!
Remember: the early trader gets the worm, or in this case the profits. This means that traders who want to take advantage of this opportunity have to be prepared by 9:30AM EST. If you wait beyond that you could end up missing out on gigantic gains.
Want to profit on Wednesday? This stock could be exactly what you're looking for.
SNDY Gets Buy Rating
Good Afternoon!
Solos Endoscopy, Inc. (OTCPINK: SNDY)
The verdict across the board on Barchart.com is “buy.”
You only need to look at the numbers to see why…
SNDY is trading with a solid 51 RSI on the daily chart which means momentum is building fast.
Currently entry is around 5 cents but consider that a bargain because in the last 12 months SNDY has traded as high as .15!
I don’t know about you but upside potential of up to 200% is very enticing. Plus, daily volatility is racing north so it looks like investors are about to pile into this 5-cent gem a little more.
And did I mention the news?
SNDY announced last week that it’s renewed its registration with the FDA. This means the company’s line of medical devices is legit as far as the biggest regulator in the US is concerned.
Talk about a vote of confidence.
At any rate this is a solid opportunity and one I hope you don’t let slip through your fingers.
Remember, this a company that has added 1633% to its historical lows – and it’s just getting started based on what I can see.
Check out the chart…
Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/SNDY
About SNDY
SNDY (Solos Endoscopy, Inc.) is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
US Medical Device Set To Reach $133 Billion By The End Of 2016
The United States remains the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016. The U.S. market value represented about 38 percent of the global medical device market in 2012. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2012, a more than 7 percent increase from the previous year.
There are more than 6,500 medical device companies in the U.S., mostly small and medium-sized enterprises (SMEs). More than 80 percent of medical device companies have fewer than 50 employees, and many (notably innovative start-up companies) have little or no sales revenue. Medical device companies are located throughout the country, but are mainly concentrated in regions known for other high-technology industries, such as microelectronics and biotechnology. The states with the highest number of medical device companies include California, Florida, New York, Pennsylvania, Michigan, Massachusetts, Illinois, Minnesota and Georgia. Other states with significant sector employment include Washington, Wisconsin, and Texas.
News Development
Solos Endoscopy, Inc. Renews FDA Registration
SNDY announced that the company has renewed the Establishment Registration & Device Listing of its endoscopic instruments with the U.S. Food and Drug Administration (FDA).
Solos Endoscopy instruments are registered and approved with the FDA; the FDA approval also covers the entire MammoView® instrument line. The company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.
Solos Endoscopy recently completed a capital restructuring initiative in order to position itself for growth over the next twelve months. The Company plans to raise capital in order to fulfill outstanding purchase orders and pursue international sales initiatives.
"Management believes that renewal of its establishment registration with the FDA along with the capital restructuring was necessary to maintain the value of our company and position us for growth. Solos has been recognized nationwide by physicians who use their instruments. It is our hope that this recognition will lead to increased sales worldwide," stated Robert Segersten, President Solos Endoscopy.
To learn more about SNDY please visit their website: http://www.solosendoscopy.com/
Make your move on SNDY now.
Warmest Regards,
Robert Davis
info@pennystocknewsletters.net
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by Stellar Media Group, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “Stellar Media” refers to Stellar Media Group, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Stellar Media’s business model is to receive financial compensation to promote public companies. We have been compensated $10k cash via bank wire by a third party, ACN, LLC, to conduct investor relations advertising and marketing for SNDY. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Stellar Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at http://pennystocknewsletters.net/disclaimer.php.
Warmest Regards,
